Fig. 2

CXCL17 increased lung metastasis in vivo. a CXCL17 increased the lung metastasis of 4T1 cells in an orthotropic model. The total number of tumor nodule per whole lung lobes was counted and averaged among the animals of each group. b The H&E staining of tumor sections. BALB/c mice were treated with PBS or recombinant mouse CXCL17 protein by intra-tracheal administration for 14 days (1 μg/mouse, 2 times/week, n = 6 per group). 4T1 were implanted into the fat pads of mice. Tumor nodules of 4T1 in the primary site and lungs were collected after 24 days of injections. c CXCL17 increased lung metastasis in human breast MDA-MB-231. Nude mice were treated with PBS or recombinant CXCL17 protein by intra-tracheal administration for 14 days (1 μg/mouse, 2 times/week, n = 6 per group). MDA-MB-231 cells were implanted into mice by tail vein injection. The MDA-MB-231 tumor nodules in the lungs of mice were collected after 90 days of injections. d The H&E staining of tumor sections. e Knockdown of CXCL17 decreased the spontaneous metastatic ability of L4T1 cells. f The H&E staining of tumor sections. CXCL17-knockdown-L4T1 were implanted into the fat pads of mice (n = 6 per group). Tumor nodules in the lungs were collected after 24 days of injections. Representative lung tissue sections were stained with H&E and photographed at × 100 magnification. Each value is the mean ± SEM; Mann-Whitney U test was performed, *p < 0.05. T tumor